Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) FCF Margin (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed FCF Margin for 4 consecutive years, with 71.31% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 3381.0% to 71.31% in Q4 2025 year-over-year; TTM through Dec 2025 was 127.6%, a 9428.0% increase, with the full-year FY2025 number at 127.6%, up 9428.0% from a year prior.
  • FCF Margin was 71.31% for Q4 2025 at Iovance Biotherapeutics, up from 132.75% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 71.31% in Q4 2025 to a low of 42587.82% in Q2 2023.
  • A 3-year average of 8926.97% and a median of 222.83% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 4226996bps in 2024, then plummeted -2813bps in 2025.
  • Iovance Biotherapeutics' FCF Margin stood at 18153.32% in 2023, then surged by 99bps to 105.12% in 2024, then surged by 32bps to 71.31% in 2025.
  • Per Business Quant, the three most recent readings for IOVA's FCF Margin are 71.31% (Q4 2025), 132.75% (Q3 2025), and 124.94% (Q2 2025).